The effects of Paxlovid on glycolipid immunometabolism in the patients with non-severe SARS-CoV-2 infection

Abstract

A wave of SARS-CoV-2 infection speedily emerged in Shanghai, China, since late February 2022. Paxlovid is a therapeutic hybrid of different compounds and a novel SARS-CoV-2 protease inhibitor by blocking an enzyme required for viral protein synthesis. It could reduce the risk of hospitalization or death by 89% as well as being benefit for immunocompromised and severe COVID-19 patients. Our registry study indicated that the days of viral elimination and inflammation factors, such as IL-6, IL-10 and interferon-α levels could be lowered by paxlovid. Days of viral elimination may be associated with fasting blood glucose, NK cells count, interferon-α levels. Lipids profiles should be monitored before and after treatment of paxlovid, especially for those who have uncontrolled lipid disorder.